Oncology
Flowchart Overview
 
1
1
1
2
1
2
1
IIT-GEORGE-I-PREDICT Phase I/II OPEN TO ACCRUAL
3
5
1
7
CELGENE-GC-LTFU-001 Phase II/III OPEN TO ACCRUAL
GRACELL-GC012F-CD19-BCMA-001 Phase I/II OPEN TO ACCRUAL
GSK-3377794-LTFU Phase I OPEN TO ACCRUAL
IIT-SHAH-IL7-IL15-CD20-19 Phase I/II OPEN TO ACCRUAL
JNJ-MY4002-CARTINUE-LTFU Phase IV OPEN TO ACCRUAL
JUNO-017004-TRANSCEND-CLL Phase I/II OPEN TO ACCRUAL
NEOGENE-NT-112-301 Phase I OPEN TO ACCRUAL
1
TRANSTHERA-TT420C2308 Phase III OPEN TO ACCRUAL
1
2
2
2
2
3
1
1
1
2
7
6
3
3
2
2
4
3
2
2
2
2
MAYO-ECHO-STUDY Phase II OPEN TO ACCRUAL
NEOGENE-NT-112-301 Phase I OPEN TO ACCRUAL
2
1
3
3
1
3
3
2
1
4
1
1
2
3
2
1
3
2
2
2
1
1
1
4
5
1
1
4
7
1
1
1
1
5
ECOG-EA4232 Phase III OPEN TO ACCRUAL
ICHNOS-ISB-2001-101 Phase I OPEN TO ACCRUAL
INCYTE-INCA-34176-254 Phase II OPEN TO ACCRUAL
LILLY-J2N-MC-JZNY Phase IV OPEN TO ACCRUAL
SWOG-MM1YA-S01 Phase II OPEN TO ACCRUAL
19
1
2
1
1
9
4
5
2
5
5
2
1
1
1
1
14
4
9
3
2
1
6
1
3
4
4
2
3
3
1
2
2
12
2
2
1
4
1
2
1
1
POLARIS-2022-001-ARGSARC Phase III OPEN TO ACCRUAL
1
2
3
2
1
1
2
2
1
2
IIT-GORE-REDIRICT Phase II OPEN TO ACCRUAL
NEOGENE-NT-112-301 Phase I OPEN TO ACCRUAL
1
6
1
1
1
3
11
6
1
3
CARNABIOSCIENCES-C1763102 Phase I OPEN TO ACCRUAL
ICHNOS-ISB-2001-101 Phase I OPEN TO ACCRUAL
IIT-GORE-REDIRICT Phase II OPEN TO ACCRUAL
13
12
3
2
2
1
1
1
4
3
3
3
1
3
3
1
3
3
1
3
3
1
3
3
1
2
2
1
1
7
4
4
1
1
1
1
2
1
1
3
1
2
4
9
5
7
6
2
2
12
1
8
1
IIT-GEORGE-I-PREDICT Phase I/II OPEN TO ACCRUAL
1
ALLIANCE-A151804 Phase N/A OPEN TO ACCRUAL